Hims offers convenient, discreet prescription hair loss treatments for men. Learn if it's right for you and what to expect.

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health ...

NEW YORK and NEW ORLEANS, March 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that ...

NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health (HIMS.N), opens new tab, known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded ...

Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded ...

Hims & Hers is making a major global expansion with its planned acquisition of Australian digital health company Eucalyptus, a good move for the company as it faces regulatory and legal challenges in ...

Novo Nordisk reversed from suing Hims over compounded GLP-1 drugs to partnering on branded obesity medication distribution, ending the legal feud and restoring a critical revenue stream. The analyst ...

Hims & Hers (HIMS) shares surged on FDA peptide tailwinds and a Novo Nordisk partnership to distribute branded Wegovy, giving the company leverage in the GLP-1 market beyond compounded alternatives.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Hims & Hers Health ...